Theravance Biopharma Inc

TBPH | NASDAQ

Price Alert Chart Builder DCF Calculator

$17.03

$0.00 (0.00%)

Nov 2, 2026, 12:40 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Oct 19, 2026

60.2

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $884.18M

1D Range

17.02 17.07

52W Range

13.08 21.03

Valuation (TTM)

PE 16.86

PB 3.05

EV/EBITDA 7.82

Valuation (NTM)

Forward PE 9.21

Forward PEG 0.34

Price Target $17.00

Cash Flow

FCF Yield 5.9%

SBC Adj. FCF Yield 3.6%

SBC Impact -37.7%

Margins

Gross Margin 89.4%

Operating Margin 4.5%

FCF Margin 49.7%

Growth (CAGR)

Revenue 3Y | 5Y 26.7% | 10.2%

Dil EPS 3Y | 5Y -55.3% | -30.8%

FCF 3Y | 5Y 32.1% | 2539.8%

Returns

ROA 11.4%

ROE 19.4%

ROIC 0.9%

Financial Health

Net Cash

$387.66M

Current Ratio 13.54

Interest Coverage 4.03

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for t...

Sector Healthcare

Industry Biotechnology

Employees 90

IPO Date May 16, 2014

Website www.theravance.com

Fiscal Year January - December

Full Company Profile

Latest News

9 months ago · zacks.com

Is the Options Market Predicting a Spike in Theravance Biopharma Stock?

Investors need to pay close attention to TBPH stock based on the movements in the options market lately.

9 months ago · zacks.com

Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

10 months ago · zacks.com

Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$17.00

Downside

-0.18%

Buy (0)

Hold (6)

Sell (0)

Analyst Details ➞